$272.11
0.99% yesterday
NYSE, Jan 17, 10:14 pm CET
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Amgen Stock price

$272.11
+6.16 2.32% 1M
-63.56 18.94% 6M
+11.47 4.40% YTD
-31.97 10.51% 1Y
+36.75 15.61% 3Y
+30.62 12.68% 5Y
+113.68 71.75% 10Y
NYSE, Closing price Fri, Jan 17 2025
+2.68 0.99%
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Key metrics

Market capitalization $146.27b
Enterprise Value $197.66b
P/E (TTM) P/E ratio 34.84
EV/FCF (TTM) EV/FCF 31.46
EV/Sales (TTM) EV/Sales 6.11
P/S ratio (TTM) P/S ratio 4.53
P/B ratio (TTM) P/B ratio 19.43
Dividend yield 3.31%
Last dividend (FY24) $9.00
Revenue growth (TTM) Revenue growth 21.38%
Revenue (TTM) Revenue $32.32b
EBIT (operating result TTM) EBIT $6.51b
Free Cash Flow (TTM) Free Cash Flow $6.28b
Cash position $9.01b
EPS (TTM) EPS $7.81
P/E forward 30.20
P/S forward 4.41
EV/Sales forward 5.96
Short interest 2.08%
Show more

Create a Free Account to create an Amgen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Amgen Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Amgen forecast:

15x Buy
44%
16x Hold
47%
3x Sell
9%

Analyst Opinions

34 Analysts have issued a Amgen forecast:

Buy
44%
Hold
47%
Sell
9%

Financial data from Amgen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
32,324 32,324
21% 21%
100%
- Direct Costs 12,858 12,858
81% 81%
40%
19,466 19,466
0% 0%
60%
- Selling and Administrative Expenses 1,619 1,619
40% 40%
5%
- Research and Development Expense 5,762 5,762
26% 26%
18%
12,085 12,085
1% 1%
37%
- Depreciation and Amortization 5,575 5,575
55% 55%
17%
EBIT (Operating Income) EBIT 6,510 6,510
25% 25%
20%
Net Profit 4,230 4,230
44% 44%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Amgen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amgen Stock News

Neutral
PRNewsWire
about 20 hours ago
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif. , Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated meta...
Positive
Reuters
one day ago
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.
Positive
The Motley Fool
2 days ago
Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while -- is one of the best formulas for earning terrific returns.
More Amgen News

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office United States
CEO Robert Bradway
Employees 26,700
Founded 1980
Website www.amgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today